EZYPOD-50

<p>
Cefpodoxime Proxetil 50 mg
</p>

<h5>Mechanism of Action</h5>
<p>
Cefpodoxime Proxetil is a prodrug that is converted in the body to cefpodoxime,
which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
</p>
<p>
This results in bacterial cell lysis and death, making it effective against
susceptible Gram-positive and Gram-negative organisms.
</p>

<h5>Indications</h5>
<ul>
<li>Upper respiratory tract infections</li>
<li>Lower respiratory tract infections</li>
<li>Ear, nose, and throat infections</li>
<li>Urinary tract infections</li>
<li>Skin and soft tissue infections</li>
</ul>

<h5>Key Benefits</h5>
<ul>
<li>Broad-spectrum antibacterial coverage</li>
<li>Suitable strength for pediatric use</li>
<li>Convenient oral administration</li>
<li>Good tolerability when used appropriately</li>
</ul>

<h5>Dosage and Administration</h5>
<p>
Dosage should be strictly as directed by the physician,
based on the patient’s age, body weight, and severity of infection.
Complete the full course of therapy as prescribed.
</p>

<h5>Safety Information</h5>
<ul>
<li>Prescription-only antibiotic</li>
<li>Use under medical supervision only</li>
<li>Not effective against viral infections</li>
<li>Caution advised in patients with renal impairment</li>
<li>Do not discontinue treatment prematurely</li>
<li>Store in a cool and dry place</li>
</ul>

<h5>Clinical Rationale</h5>
<p>
EZYPOD-50 offers a lower-dose cefpodoxime option suitable for pediatric
and mild to moderate infections, providing reliable oral cephalosporin
therapy when used judiciously and according to prescription.
</p>